This breakthrough study shows the antiviral drug obeldesivir administered once daily orally was effective against a lethal challenge of Ebola in non human primates.
This is an NIH funded study, the likes of which are being cut by the current administration.
www.science.org/doi/10.1126/...
This is an NIH funded study, the likes of which are being cut by the current administration.
www.science.org/doi/10.1126/...
The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection
Oral treatment with obeldesivir protects macaques from lethal infection with Ebola virus.
www.science.org
March 23, 2025 at 1:45 PM
This breakthrough study shows the antiviral drug obeldesivir administered once daily orally was effective against a lethal challenge of Ebola in non human primates.
This is an NIH funded study, the likes of which are being cut by the current administration.
www.science.org/doi/10.1126/...
This is an NIH funded study, the likes of which are being cut by the current administration.
www.science.org/doi/10.1126/...
Anti-viral drug obeldesivir has been shown to prevent against fatal ebola infection in rhesus macaques, which could greatly reduce the cost of managing ebola outbreaks and save lives 🧪
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection
Oral treatment with obeldesivir protects macaques from lethal infection with Ebola virus.
www.science.org
March 15, 2025 at 1:34 PM
Anti-viral drug obeldesivir has been shown to prevent against fatal ebola infection in rhesus macaques, which could greatly reduce the cost of managing ebola outbreaks and save lives 🧪
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Very promising to see that Obeldesivir, an orally bioavailable nucleoside analog prodrug was effective against a lethal challenge of Marburg virus in a primate model of disease when administered within 24 hours of infection for a 10 day course 🧪
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates - Nature Medicine
The oral drug obeldesivir confers 80% survival when given after lethal Marburg virus exposure in cynomolgus macaques and also delays viral replication and disease onset, suggesting a potential treatme...
www.nature.com
January 13, 2025 at 6:27 PM
Very promising to see that Obeldesivir, an orally bioavailable nucleoside analog prodrug was effective against a lethal challenge of Marburg virus in a primate model of disease when administered within 24 hours of infection for a 10 day course 🧪
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Working with colleagues Gilead, we developed oral drugs to treat filoviruses like Marburg virus and ebolaviruses www.nature.com/articles/s41...
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates - Nature Medicine
The oral drug obeldesivir confers 80% survival when given after lethal Marburg virus exposure in cynomolgus macaques and also delays viral replication and disease onset, suggesting a potential treatme...
www.nature.com
January 29, 2025 at 1:45 AM
Working with colleagues Gilead, we developed oral drugs to treat filoviruses like Marburg virus and ebolaviruses www.nature.com/articles/s41...
Obeldesivir, an oral drug, shows promise for #Marburg virus postexposure protection with up to 90% mortality prevention in nonhuman primates. Let's fight MARV! 🚀 PMID:39805309, Nat Med 2025, @NatureMedicine https://doi.org/10.1038/s41591-025-03496-y 🧪
February 25, 2025 at 5:10 AM
Obeldesivir, an oral drug, shows promise for #Marburg virus postexposure protection with up to 90% mortality prevention in nonhuman primates. Let's fight MARV! 🚀 PMID:39805309, Nat Med 2025, @NatureMedicine https://doi.org/10.1038/s41591-025-03496-y 🧪
It is a timely and critical discovery! www.nature.com/articles/s41...
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates - Nature Medicine
The oral drug obeldesivir confers 80% survival when given after lethal Marburg virus exposure in cynomolgus macaques and also delays viral replication and disease onset, suggesting a potential treatme...
www.nature.com
January 15, 2025 at 10:26 PM
It is a timely and critical discovery! www.nature.com/articles/s41...
Obeldesivir shows promise against RSV, reducing infection in African green monkeys with oral dosing. A new hope for effective RSV treatment! PMID:40645925, Nat Commun 2025, @NatureComms https://doi.org/10.1038/s41467-025-61595-3 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys | Nature Communications
Respiratory syncytial virus (RSV) is a significant cause of morbidity and mortality in high-risk populations. Although prophylactic options are available, there are no effective oral therapeutics for RSV infection. Obeldesivir (ODV) is an orally bioavailable prodrug of the nucleoside analog GS-441524, which is converted intracellularly to its active nucleoside triphosphate and inhibits the RSV RNA polymerase. Here we report the potent antiviral activity of ODV against geographically and temporally diverse RSV A and B clinical isolates (EC50: 0.20–0.66 μM). Resistance selection studies with ODV and GS-441524 against RSV identify a single amino acid substitution, I777L, in the L polymerase with reduced susceptibility (3.3-3.8-fold) to ODV and GS-441524, indicating a high barrier for resistance development. In an African green monkey RSV infection model, once-daily oral ODV doses of 30 or 90 mg/kg initiated ~24 hours post-infection significantly reduces log10 viral RNA copies/mL × day are
doi.org
August 23, 2025 at 12:10 AM
6/ Therapeutics WHO has prioritized:
Treatment: REGN3479 + MBP134 (monoclonal antibodies), Remdesivir (IV antiviral)
Post-exposure prophylaxis: Obeldesivir (oral antiviral) promising but needs a clinical trial first
None approved. All need ethics review, regulatory sign-off, import permits etc.
Treatment: REGN3479 + MBP134 (monoclonal antibodies), Remdesivir (IV antiviral)
Post-exposure prophylaxis: Obeldesivir (oral antiviral) promising but needs a clinical trial first
None approved. All need ethics review, regulatory sign-off, import permits etc.
May 23, 2026 at 11:26 AM
6/ Therapeutics WHO has prioritized:
Treatment: REGN3479 + MBP134 (monoclonal antibodies), Remdesivir (IV antiviral)
Post-exposure prophylaxis: Obeldesivir (oral antiviral) promising but needs a clinical trial first
None approved. All need ethics review, regulatory sign-off, import permits etc.
Treatment: REGN3479 + MBP134 (monoclonal antibodies), Remdesivir (IV antiviral)
Post-exposure prophylaxis: Obeldesivir (oral antiviral) promising but needs a clinical trial first
None approved. All need ethics review, regulatory sign-off, import permits etc.
Read our December issue!
Featuring testing obeldesivir for COVID-19 therapy, measles transmission patterns in Italy, and single dose of HPV vaccine in Costa Rica.
www.thelancet.com/issue/S1473-...
Featuring testing obeldesivir for COVID-19 therapy, measles transmission patterns in Italy, and single dose of HPV vaccine in Costa Rica.
www.thelancet.com/issue/S1473-...
November 20, 2025 at 5:51 AM
Read our December issue!
Featuring testing obeldesivir for COVID-19 therapy, measles transmission patterns in Italy, and single dose of HPV vaccine in Costa Rica.
www.thelancet.com/issue/S1473-...
Featuring testing obeldesivir for COVID-19 therapy, measles transmission patterns in Italy, and single dose of HPV vaccine in Costa Rica.
www.thelancet.com/issue/S1473-...
New research shows there's real promise that Gilead's antiviral #obeldesivir could be used to treat #Ebola Sudan & possibly other types of Ebola & #Marburg. It could make responses far easier: it's a pill, it doesn't require cold chain & it's not expensive to make. www.statnews.com/2024/03/14/e...
March 14, 2024 at 6:30 PM
New research shows there's real promise that Gilead's antiviral #obeldesivir could be used to treat #Ebola Sudan & possibly other types of Ebola & #Marburg. It could make responses far easier: it's a pill, it doesn't require cold chain & it's not expensive to make. www.statnews.com/2024/03/14/e...
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo reut.rs/3SR6t4D
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak in Congo and Uganda.
reut.rs
July 14, 2026 at 1:10 PM
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo reut.rs/3SR6t4D
Antiviraltabletten Obeldesivir hade viss effekt i Fas 3-studier, men ingen kioskvältare vad jag kan förstå.
Obeldesivir är en prodrog (dvs kemiskt paketerad till ett förstadium i tablettform) av antiviralen GS-441524 som i sin tur är en metabolit av Remdesvir.
Puh.
www.natap.org/2024/IDWeek/...
Obeldesivir är en prodrog (dvs kemiskt paketerad till ett förstadium i tablettform) av antiviralen GS-441524 som i sin tur är en metabolit av Remdesvir.
Puh.
www.natap.org/2024/IDWeek/...
Obeldesivir Reduced SARS-CoV-2 Infectious Titers in the BIRCH Phase 3 Clinical Trial
www.natap.org
December 26, 2024 at 11:49 PM
Antiviraltabletten Obeldesivir hade viss effekt i Fas 3-studier, men ingen kioskvältare vad jag kan förstå.
Obeldesivir är en prodrog (dvs kemiskt paketerad till ett förstadium i tablettform) av antiviralen GS-441524 som i sin tur är en metabolit av Remdesvir.
Puh.
www.natap.org/2024/IDWeek/...
Obeldesivir är en prodrog (dvs kemiskt paketerad till ett förstadium i tablettform) av antiviralen GS-441524 som i sin tur är en metabolit av Remdesvir.
Puh.
www.natap.org/2024/IDWeek/...
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates - Nature Medicine
The oral drug obeldesivir confers 80% survival when given after lethal Marburg virus exposure in cynomolgus macaques and also delays viral replication and disease onset, suggesting a potential treatme...
www.nature.com
January 13, 2025 at 2:04 PM
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates
@naturemedicine.bsky.social
www.nature.com/articles/s41...
@naturemedicine.bsky.social
www.nature.com/articles/s41...
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates - Nature Medicine
The oral drug obeldesivir confers 80% survival when given after lethal Marburg virus exposure in cynomolgus macaques and also delays viral replication and disease onset, suggesting a potential treatme...
www.nature.com
January 13, 2025 at 6:24 PM
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates
@naturemedicine.bsky.social
www.nature.com/articles/s41...
@naturemedicine.bsky.social
www.nature.com/articles/s41...
Fresh work from our group in collaboration with @GileadSciences in @NatureMedicine demonstrating post exposure protection against Marburg virus in NHPs using oral Obeldesivir. @UTMBProvost @UTMBPresident @utmbhealth with support from @NIAIDNews www.nature.com/articles/s41...
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates - Nature Medicine
The oral drug obeldesivir confers 80% survival when given after lethal Marburg virus exposure in cynomolgus macaques and also delays viral replication and disease onset, suggesting a potential treatme...
www.nature.com
January 13, 2025 at 10:36 PM
Fresh work from our group in collaboration with @GileadSciences in @NatureMedicine demonstrating post exposure protection against Marburg virus in NHPs using oral Obeldesivir. @UTMBProvost @UTMBPresident @utmbhealth with support from @NIAIDNews www.nature.com/articles/s41...
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates - Nature Medicine
The oral drug obeldesivir confers 80% survival when given after lethal Marburg virus exposure in cynomolgus macaques and also delays viral replication and disease onset, suggesting a potential treatme...
www.nature.com
January 24, 2025 at 3:42 PM
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Texas researchers found that the oral drug obeldesivir (ODV) gave 100% protection to rhesus macaques and 80% to cynomolgus macaques against lethal Ebola when given 24 hours after exposure.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection
Oral treatment with obeldesivir protects macaques from lethal infection with Ebola virus.
www.science.org
March 17, 2025 at 4:24 PM
Texas researchers found that the oral drug obeldesivir (ODV) gave 100% protection to rhesus macaques and 80% to cynomolgus macaques against lethal Ebola when given 24 hours after exposure.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Oral obeldesivir significantly protects nonhuman primates from Marburg virus after exposure, showing promise for outbreak management.
by Cross RW, Woolsey C (...) Geisbert TW et 13 al. in Nat Med #MedSky
📖 read the article: https://www.nature.com/articles/s41591-025-03496-y
by Cross RW, Woolsey C (...) Geisbert TW et 13 al. in Nat Med #MedSky
📖 read the article: https://www.nature.com/articles/s41591-025-03496-y
January 22, 2025 at 4:33 PM
Oral obeldesivir significantly protects nonhuman primates from Marburg virus after exposure, showing promise for outbreak management.
by Cross RW, Woolsey C (...) Geisbert TW et 13 al. in Nat Med #MedSky
📖 read the article: https://www.nature.com/articles/s41591-025-03496-y
by Cross RW, Woolsey C (...) Geisbert TW et 13 al. in Nat Med #MedSky
📖 read the article: https://www.nature.com/articles/s41591-025-03496-y
There are no approved vaccines or therapeutics for #Bundibugyo, but several promising candidates are being prioritized by WHO for trials
Therapeutics:
💉 MBP134
💉 Maftivimab
💊 Remdesivir & Obeldesivir
Vaccines:
🧬 rVSV-Bundibugyo (IAVI)
🧬 Oxford ChAdOx1 Bundibugyo
www.who.int/news/item/28...
Therapeutics:
💉 MBP134
💉 Maftivimab
💊 Remdesivir & Obeldesivir
Vaccines:
🧬 rVSV-Bundibugyo (IAVI)
🧬 Oxford ChAdOx1 Bundibugyo
www.who.int/news/item/28...
Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus
In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its exper...
www.who.int
May 28, 2026 at 9:46 PM
There are no approved vaccines or therapeutics for #Bundibugyo, but several promising candidates are being prioritized by WHO for trials
Therapeutics:
💉 MBP134
💉 Maftivimab
💊 Remdesivir & Obeldesivir
Vaccines:
🧬 rVSV-Bundibugyo (IAVI)
🧬 Oxford ChAdOx1 Bundibugyo
www.who.int/news/item/28...
Therapeutics:
💉 MBP134
💉 Maftivimab
💊 Remdesivir & Obeldesivir
Vaccines:
🧬 rVSV-Bundibugyo (IAVI)
🧬 Oxford ChAdOx1 Bundibugyo
www.who.int/news/item/28...
However, it did reduce viral RNA copy number & infectious titer, demonstrating its ability to inhibit #SARSCoV2 replication. Additionally, #obeldesivir resulted in numerically faster symptom alleviation.
academic.oup.com/cid/advance-... @cidjournal.bsky.social
academic.oup.com/cid/advance-... @cidjournal.bsky.social
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
AbstractBackground. Obeldesivir is an oral nucleoside analog prodrug inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Methods. Non
academic.oup.com
July 28, 2025 at 10:07 PM
However, it did reduce viral RNA copy number & infectious titer, demonstrating its ability to inhibit #SARSCoV2 replication. Additionally, #obeldesivir resulted in numerically faster symptom alleviation.
academic.oup.com/cid/advance-... @cidjournal.bsky.social
academic.oup.com/cid/advance-... @cidjournal.bsky.social
Omdat goed nieuws ook wel eens fijn is: apen genezen na een pil met antiviraal middel Obeldesivir van Ebola. medicalxpress.com/news/2025-03...
Ebola-infected monkeys cured with a pill, sparking human treatment hopes
Monkeys infected with Ebola can be cured with a pill, according to a new study out Friday that could pave the way for more practical, affordable treatments in humans.
medicalxpress.com
March 17, 2025 at 8:27 AM
Omdat goed nieuws ook wel eens fijn is: apen genezen na een pil met antiviraal middel Obeldesivir van Ebola. medicalxpress.com/news/2025-03...
MSF published a technical brief analysing access challenges concerning three Bundibugyo Ebola Virus therapeutic candidates - MBP134, remdesivir, and obeldesivir.
msfaccess.org/therapeutics...
msfaccess.org/therapeutics...
Therapeutics for the 2026 Bundibugyo Ebola disease outbreak: Access gaps and recommendations
Technical brief on Ebola therapeutics and key factors affecting access
msfaccess.org
September 24, 2026 at 11:23 AM
MSF published a technical brief analysing access challenges concerning three Bundibugyo Ebola Virus therapeutic candidates - MBP134, remdesivir, and obeldesivir.
msfaccess.org/therapeutics...
msfaccess.org/therapeutics...
Obeldesivir, a SARS-CoV-2 antiviral, showed low risk of drug interactions in Phase I trials.
Minor exposure changes were not clinically relevant, and the drug was well tolerated, supporting its broad antiviral potential.
ascpt.onlinelibrary.wiley.com/doi/10.1002/...
Minor exposure changes were not clinically relevant, and the drug was well tolerated, supporting its broad antiviral potential.
ascpt.onlinelibrary.wiley.com/doi/10.1002/...
Clinical Evaluation of Drug–Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent
Obeldesivir is an oral nucleoside analog prodrug inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase and other viral polymerases. Here, two Phase I studies evaluated potential drug–drug interactions...
ascpt.onlinelibrary.wiley.com
January 31, 2025 at 6:21 PM
Obeldesivir, a SARS-CoV-2 antiviral, showed low risk of drug interactions in Phase I trials.
Minor exposure changes were not clinically relevant, and the drug was well tolerated, supporting its broad antiviral potential.
ascpt.onlinelibrary.wiley.com/doi/10.1002/...
Minor exposure changes were not clinically relevant, and the drug was well tolerated, supporting its broad antiviral potential.
ascpt.onlinelibrary.wiley.com/doi/10.1002/...
